Literature DB >> 11768928

Varicella zoster virus. Recent advances in management.

P Rajan1, J K Rivers.   

Abstract

OBJECTIVE: To provide an update on strategies for managing varicella zoster virus (VZV) and for preventing and treating established postherpetic neuralgia (PHN). QUALITY OF EVIDENCE: Treatment guidelines are based on randomized clinical trials. Recommendations concerning other aspects of VZV management (e.g., vaccination) are based mainly on expert opinion. MAIN MESSAGE: Varicella and herpes zoster caused by VZV can give rise to serious morbidity and mortality and should be treated. For preventing chickenpox, safe and effective immunization is widely recommended. Treating varicella-exposed seronegative pregnant women requires special attention because the virus can harm expectant mothers, fetuses, and newborns. The antiviral drugs, acyclovir, valacyclovir, and famciclovir, have been approved for treating herpes zoster and have a role in reducing the duration of PHN. Established PHN can be managed with analgesics, tricyclic antidepressants, and other agents.
CONCLUSION: Vaccination and antiviral and other systemic agents can substantially reduce the morbidity associated with VZV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768928      PMCID: PMC2018456     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  37 in total

1.  Primary varicella pneumonia.

Authors:  S KRUGMAN; C H GOODRICH; R WARD
Journal:  N Engl J Med       Date:  1957-10-31       Impact factor: 91.245

Review 2.  Consensus: varicella-zoster infections in pregnancy and the perinatal period.

Authors:  C G Prober; A A Gershon; C Grose; G H McCracken; J D Nelson
Journal:  Pediatr Infect Dis J       Date:  1990-12       Impact factor: 2.129

3.  Acyclovir in herpes zoster.

Authors:  N A Peterslund; K Seyer-Hansen; J Ipsen; V Esmann; H Schonheyder; H Juhl
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

Review 4.  Do corticosteroids prevent postherpetic neuralgia? A review of the evidence.

Authors:  B T Post; J T Philbrick
Journal:  J Am Acad Dermatol       Date:  1988-03       Impact factor: 11.527

5.  Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study.

Authors:  P J van den Broek; J W van der Meer; J D Mulder; J Versteeg; H Mattie
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

6.  Postlicensure safety surveillance for varicella vaccine.

Authors:  R P Wise; M E Salive; M M Braun; G T Mootrey; J F Seward; L G Rider; P R Krause
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 7.  Varicella zoster virus.

Authors:  M L McCrary; J Severson; S K Tyring
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

Review 8.  Systemic antivirals in herpesvirus infections.

Authors:  J J Sasadeusz; S L Sacks
Journal:  Dermatol Clin       Date:  1993-01       Impact factor: 3.478

9.  Oral acyclovir in the treatment of herpes zoster in general practice.

Authors:  P Morton; A N Thomson
Journal:  N Z Med J       Date:  1989-03-08

10.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more
  1 in total

1.  Primary Varicella or Herpes Zoster? An Educational Case Report From the Primary Care Clinic.

Authors:  Ana K Gómez-Gutiérrez; Areli A Flores-Camargo; Andrea Casillas Fikentscher; Eder Luna-Ceron
Journal:  Cureus       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.